1. Clinical Overview
Octreotide acetate is a synthetic octapeptide analogue of the natural hormone somatostatin. It mimics somatostatin's pharmacological actions but has a significantly longer duration of effect. It is a potent inhibitor of growth hormone, glucagon, and insulin, and suppresses the secretion of various gastroenteropancreatic peptides. In the Indian market, it is a critical drug for managing acromegaly, carcinoid syndrome, and acute variceal bleeding.
| Onset | Duration | Bioavailability |
|---|---|---|
| Subcutaneous: Within 30 minutes. Intravenous: Immediate. | Subcutaneous: Up to 12 hours (dose-dependent). | Approximately 100% following subcutaneous injection. |
2. Mechanism of Action
Octreotide binds with high affinity to somatostatin receptors (primarily subtypes 2 and 5). This binding inhibits the secretion of numerous hormones and bioactive peptides. It reduces splanchnic blood flow and portal pressure, inhibits gallbladder contractility and bile secretion, and modulates intestinal fluid/electrolyte transport.
3. Indications & Uses
- Acromegaly: Long-term treatment to reduce GH and IGF-1 levels after inadequate surgery/radiotherapy or while awaiting radiotherapy effect.
- Control of symptoms in patients with metastatic carcinoid tumors (flushing, diarrhea).
- Treatment of profuse watery diarrhea associated with Vasoactive Intestinal Peptide-secreting tumors (VIPomas).
- Acute bleeding from esophageal varices (adjunct to endoscopic therapy).
4. Dosage & Administration
Adult Dosage: Acromegaly: Initial: 0.05-0.1 mg SC every 8 hrs. Titrate based on GH/IGF-1. Usual: 0.2-0.3 mg/day. Max: 1.5 mg/day. Carcinoid/VIPoma: 0.1-0.2 mg SC 2-3 times daily. Acute Variceal Bleed: 0.1 mg IV bolus, followed by 0.025-0.05 mg/hr IV infusion for 2-5 days.
Administration: For SC injection: Rotate injection sites (thigh, abdomen, buttock). Avoid same site consecutively. For IV use: Dilute in 50-100 mL of Normal Saline or 5% Dextrose. Use infusion pump. Ampoule must be inspected for particulate matter before use.
5. Side Effects
Common side effects may include:
- Injection site pain, redness, stinging, swelling.
- Nausea, abdominal pain, diarrhea, flatulence.
- Headache, dizziness.
- Hyperglycemia or hypoglycemia (transient).
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Cyclosporine | Octreotide may decrease cyclosporine levels; monitor levels closely. | Major |
| Insulin, Oral Hypoglycemics (e.g., Glibenclamide) | Octreotide alters glycemic control (can cause hypo- or hyperglycemia); frequent glucose monitoring required. | Major |
| Bromocriptine | Octreotide increases bioavailability of bromocriptine. | Moderate |
| Beta-blockers (e.g., Propranolol) | Additive bradycardic effect; monitor heart rate. | Moderate |
| Calcium Channel Blockers (e.g., Verapamil) | May potentiate bradycardia. | Moderate |
| Drugs metabolized by CYP3A4 (e.g., Midazolam) | Possible decreased clearance; monitor for increased effects. | Moderate |
7. Patient Counselling
- Do rotate injection sites to prevent lipodystrophy or local reactions.
- Do monitor blood sugar regularly if diabetic.
- Do report severe abdominal pain, yellowing of skin/eyes, or clay-colored stools (signs of gallbladder/pancreas issues).
- Don't stop the medication abruptly without consulting your doctor.
- Don't use if the solution is discolored or contains particles.
8. Toxicology & Storage
Overdose: Severe hypoglycemia, lethargy, weakness, dizziness, nausea, diarrhea, abdominal cramps, flushing, bradycardia, cardiac arrest.
Storage: Store unopened ampoules/vials between 2°C and 8°C (refrigerate). Do not freeze. Protect from light. After opening/dilution, use immediately. If necessary, diluted solution for IV infusion is stable at room temperature for up to 24 hours.